Table 2.
Study subject characteristics and summary of sequencing results for CDKN2A, CDK4, and exon 5 of GNAQ and GNA11.
Study Subject ID | Pedigree ID | Individual | Individual | Individual | Individual | Individual | Pedigree | Pedigree | Pedigree | Pedigree | Pedigree |
---|---|---|---|---|---|---|---|---|---|---|---|
History of cutaneous melanoma | History of uveal melanoma | History of blue nevi | GNAQ exon 5 genotyping results | GNA11 exon 5 genotyping results | Number of cutaneous melanomas | Number of blue nevi | Number of uveal melanoma | CDKN2A genotyping results | CDK4 genotyping results | ||
1 | A | Yes | No | Yes | WT | WT | 7 | 1 | 0 | WT | WT |
2 | B | Yes | No | Yes | WT | WT | 17 | 1 | 0 | WT | WT |
3 | C | Yes | Yes | No | WT | WT | 3 | 0 | 1 | WT | WT |
4 | D | Yes | No | Yes | WT | WT | 9 | 1 | 0 | WT | WT |
5 | E | Yes | No | Yes | WT | WT | 42 | 1 | 0 | WT | WT |
6 | F | No | No | Yes | WT | WT | 4 | 1 | 0 | WT | WT |
7 | G | Yes | Yes | No | WT | WT | 8 | 0 | 1 | WT | WT |
8 | H | No | No | Yes | WT | WT | 4 | 3 | 1 | A148T G > A (p16) | WT |
9 | H | No | No | Yes | WT | WT | – | – | – | A148T G > A (p16) | WT |
10 | H | Yes | No | No | WT | WT | – | – | – | A148T G > A (p16) | WT |
11 | H | No | No | Yes | WT | WT | – | – | – | A148T G > A (p16) | WT |
12 | H | Yes | No | No | WT | WT | – | – | – | A148T G > A (p16) | WT |
13 | I | No | No | Yes | WT | WT | 3 | 2 | 0 | Not determined | Not determined |
14 | J | Yes | No | Yes | WT | WT | 6 | 2 | 0 | Not determined | Not determined |
15 | J | No | No | Yes | WT | WT | – | – | – | Not determined | Not determined |
16 | K | No | No | Yes | WT | WT | 3 | 1 | 0 | WT | WT |
17 | L | No | No | Yes | WT | WT | 2 | 1 | 0 | Not determined | Not determined |
18 | M | Yes | No | No | WT | WT | 5 | 0 | 1 | WT | WT |
19 | M | Yes | No | No | WT | WT | – | – | – | WT | WT |
20 | M | Yes | Yes | No | WT | WT | – | – | – | WT | WT |
21 | M | Yes | No | No | WT | WT | – | – | – | WT | WT |
22 | M | Yes | No | No | WT | WT | – | – | – | WT | WT |
WT, wild-type.